BackShanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Total Current Liabilities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s total current liabilities is $260M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$255.67M
↑ 44.54% YoYΔ $78.78M vs prior year quarter

Peer trimmed avg / median

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Total Current Liabilities History

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. vs. peers: Total Current Liabilities Comparison

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. (688505.SS) FAQ

The latest total current liabilities for 688505.SS is $260M as of September 2026. That compares with $180M in the prior-year period — up 44.5% year over year. Investors often review this figure alongside Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 688505.SS's total current liabilities moved from $180M to $260M — a 44.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s operating scale or balance-sheet position.

A total current liabilities figure of $260M for 688505.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 688505.SS's total current liabilities ($260M), review year-over-year change from $180M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.